Sign Out
Pharmacodynamics: Rivaroxaban inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa (FXa).
Pharmacokinetics: Absorption: Rapid.
Bioavailability: Absolute bioavailability: 10 mg dose: ~80% to 100%;
20 mg dose: ~66% (fasting; increased with food).
Time to peak, plasma: 2 to 4 hours.
Distribution: Vdss: ~50 L.
Protein binding: ~92% to 95% (primarily to albumin).
Metabolism: Hepatic via CYP3A4/5 and CYP2J2.
Excretion: Urine [66% primarily via active tubular secretion (~36% as unchanged drug; 30% as inactive metabolites)]; feces (28% [7% as unchanged drug; 21% as inactive metabolites]).
Half-life elimination: Terminal: 5 to 9 hours; Elderly: 11 to 13 hours.
